Transdermal delivery of pramipexole using microneedle technology for the potential treatment of Parkinson’s disease

  • Mary B McGuckin

Student thesis: Doctoral ThesisDoctor of Philosophy


Parkinson's disease is a debilitating neurodegenerative disease primarily impacting neurones responsible for dopamine production within the brain. Pramipexole (PRA) is a dopamine agonist that enhances dopamine neurotransmission, restoring balance and alleviating symptoms. The work presented here shows how transdermal drug delivery, using microneedle (MN) technology, is a promising avenue for addresing issues with current oral treatment of PRA. In vivo investigations confirmed the successful delivery of PRA from dissolving MNs (Cmax = 511.00 ng/mL, Tmax = 4 hrs) and hydrogel-forming MNs (Cmax = 328.30 ng/mL, Tmax = 24 hrs). Notably, both types of MNs sustained PRA plasma levels over a 5-day period compared to 48 hrs following oral administration
Date of AwardJul 2024
Original languageEnglish
Awarding Institution
  • Queen's University Belfast
SponsorsNorthern Ireland Department for the Economy
SupervisorEneko Larrañeta (Supervisor) & Ryan Donnelly (Supervisor)


  • Parkinson's disease
  • pramipexole
  • microneedle
  • transdermal
  • drug delivery

Cite this